FOXP3型
白细胞介素2受体
细胞生物学
体内
体外
西罗莫司
生物
细胞生长
癌症研究
免疫学
细胞毒性T细胞
免疫系统
生物化学
生物技术
作者
Manuela Battaglia,Angela Stabilini,Maria Grazia Roncarolo
出处
期刊:Blood
[American Society of Hematology]
日期:2005-06-15
卷期号:105 (12): 4743-4748
被引量:1081
标识
DOI:10.1182/blood-2004-10-3932
摘要
Abstract Rapamycin is an immunosuppressive compound that is currently used to prevent acute graft rejection in humans. In addition, rapamycin has been shown to allow operational tolerance in murine models. However, a direct effect of rapamycin on T regulatory (Tr) cells, which play a key role in induction and maintenance of peripheral tolerance, has not been demonstrated so far. Here, we provide new evidence that rapamycin selectively expands the murine naturally occurring CD4+CD25+FoxP3+ Tr cells in vitro. These expanded Tr cells suppress proliferation of syngeneic T cells in vitro and prevent allograft rejection in vivo. Interestingly, rapamycin does not block activation-induced cell death and proliferation of CD4+ T cells in vitro. Based on this new mode of action, rapamycin can be used to expand CD4+CD25+FoxP3+ Tr cells for ex vivo cellular therapy in T-cell-mediated diseases. (Blood. 2005;105:4743-4748)
科研通智能强力驱动
Strongly Powered by AbleSci AI